Lipase Inhibitor

Management of obesity, including weight loss and weight management when used in conjunction with a reduced-calorie diet; reduce the risk of weight regain after prior weight loss; indicated for obese patients with an initial body mass index (BMI) greater than or equal to 30 kg/m² or greater than or equal to 27 kg/m² in the presence of other risk factors

5'0"

140 lb: BMI = 27

150 lb: BMI = 29

160 lb: BMI = 31

170 lb: BMI = 33

180 lb: BMI = 35

190 lb: BMI = 37

200 lb: BMI = 39

210 lb: BMI = 41

220 lb: BMI = 43

230 lb: BMI = 45

240 lb: BMI = 47

250 lb: BMI = 49

5'3"

140 lb: BMI = 25

150 lb: BMI = 27

160 lb: BMI = 28

170 lb: BMI = 30

180 lb: BMI = 32

190 lb: BMI = 34

200 lb: BMI = 36

210 lb: BMI = 37

220 lb: BMI = 39

230 lb: BMI = 41

240 lb: BMI = 43

250 lb: BMI = 44

5'6"

140 lb: BMI = 23

150 lb: BMI = 24

160 lb: BMI = 26

170 lb: BMI = 28

180 lb: BMI = 29

190 lb: BMI = 31

200 lb: BMI = 32

210 lb: BMI = 34

220 lb: BMI = 36

230 lb: BMI = 37

240 lb: BMI = 39

250 lb: BMI = 40

5'9"

140 lb: BMI = 21

150 lb: BMI = 22

160 lb: BMI = 24

170 lb: BMI = 25

180 lb: BMI = 27

190 lb: BMI = 28

200 lb: BMI = 30

210 lb: BMI = 31

220 lb: BMI = 33

230 lb: BMI = 34

240 lb: BMI = 36

250 lb: BMI = 37

6'0"

140 lb: BMI = 19

150 lb: BMI = 20

160 lb: BMI = 22

170 lb: BMI = 23

180 lb: BMI = 25

190 lb: BMI = 26

200 lb: BMI = 27

210 lb: BMI = 29

220 lb: BMI = 30

230 lb: BMI = 31

240 lb: BMI = 33

250 lb: BMI = 34

6'3"

140 lb: BMI = 18

150 lb: BMI = 19

160 lb: BMI = 20

170 lb: BMI = 21

180 lb: BMI = 23

190 lb: BMI = 24

200 lb: BMI = 25

210 lb: BMI = 26

220 lb: BMI = 28

230 lb: BMI = 29

240 lb: BMI = 30

250 lb: BMI = 31

B

There are no adequate and well-controlled studies of orlistat in pregnant women. Because animal reproductive studies are not always predictive of human response, orlistat is not recommended for use during pregnancy. Teratogenicity studies were conducted in rats and rabbits at doses up to 800 mg/kg/day. Neither study showed embryotoxicity or teratogenicity. This dose is 23 and 47 times the daily human dose calculated on a body surface area basis for rats and rabbits, respectively. It is not know if orlistat is secreted in human milk. Therefore, it should not be taken by nursing women.

Chronic malabsorption syndrome or cholestasis; hypersensitivity to orlistat or any component

Patients should be advised to adhere to dietary guidelines; gastrointestinal adverse events may increase if taken with a diet high in fat (>30% total daily calories from fat). The daily intake of fat should be distributed over three main meals. If taken with any one meal very high in fat, the possibility of gastrointestinal effects increases. Patients should be counseled to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition because orlistat has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene. The supplement should be taken once daily at least 2 hours before or after the administration of orlistat (ie, bedtime). Some patients may develop increased levels of urinary oxalate following treatment; caution should be exercised when prescribing it to patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis. As with any weight-loss agent, the potential exists for misuse in appropriate patient populations (eg, patients with anorexia nervosa or bulimia). Write/fill Rx carefully. Dispensing errors have been made between Xenical®(orlistat) and Xeloda™ (capecitabine).

Percentage unknown: Headache, dizziness, sleep disorder, anxiety, depression, dry skin, rash, oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, fecal incontinence, back pain, pain of lower extremities, arthritis, myalgia, joint disorder, tendonitis, otitis, influenza; respiratory tract infection; ear, nose, and throat symptoms

Single doses of 800 mg and multiple doses of up to 400 mg 3 times daily for 15 days have been studied in normal weight and obese patients without significant adverse findings; in case of significant overdose, it is recommended that the patient be observed for 24 hours

Decreased effect: Vitamin K absorption may be decreased when taken with orlistat

120 mg 3 times/day with each main meal containing fat (during or up to 1 hour after the meal); omit dose if meal is occasionally missed or contains no fat

Changes in coagulation parameters

No information available to require special precautions

No effects or complications reported

Take this medication exactly as ordered; do not alter prescribed dose without consulting prescriber. Maintain prescribed diet (high fat meals may result in GI distress), exercise regimen, and vitamin supplements as prescribed. You may experience dizziness or lightheadedness (use caution when driving or engaging in tasks requiring alertness until response to drug is known) or increased flatus and fecal urgency (this may lessen with continued use). Report persistent back, muscle, or joint pain; signs of respiratory tract infection or flu-like symptoms; skin rash or irritation; or other reactions. Breast-feeding precautions: Breast-feeding is not recommended.

Capsule: 120 mg